Facebook PixelCan we foresee pharmaceutical markets dominated by biosimilars in future?
Brainstorming
Brainstorming
Brainstorming session

Can we foresee pharmaceutical markets dominated by biosimilars in future?

Can we foresee pharmaceutical markets dominated by biosimilars in future?

Image credit: https://consultqd.clevelandclinic.org/generics-and-biosimilars-in-multiple-sclerosis-navigating-a-new-therapy-landscape/

By Kritika Bansal on Nov 12, 2020

[1] Konstantinidou, S., Papaspiliou, A., Kokkotou, E."Current and future roles of biosimilars in oncology practice (Review)". Oncology Letters 19.1 (2020): 45-51.

[2] Kim, HoUng et al. “The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.” Drugs vol. 80,2 (2020): 99-113. doi:10.1007/s40265-020-01256-5

Creative contributions

no easy entry, as everything new

[1] Biosimilars: what clinicians should know. 2012, 120 (26):5111-7 Blood

by Martina Pesce on Nov 13, 2020

I imagine a bit of patients resistance

[1] [1] E. Dubé, M. Vivion, and N. E. MacDonald, “Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: Influence, impact and implications,” Expert Review of Vaccines. 2014.

by Martina Pesce on Nov 13, 2020

Questions first: But why are they different if they have the same clinical properties?

by Subash Chapagain on Nov 13, 2020

Your creative contribution

0 / 200

Added via the text editor